<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098874</url>
  </required_header>
  <id_info>
    <org_study_id>FMCH-2019-28219</org_study_id>
    <secondary_id>R01DA047287</secondary_id>
    <nct_id>NCT04098874</nct_id>
  </id_info>
  <brief_title>Bupropion for the Prevention of Postpartum Smoking Relapse</brief_title>
  <official_title>Bupropion for the Prevention of Postpartum Smoking Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This two-arm, double-blind, placebo-controlled randomized clinical trial will enroll pregnant
      women who quit smoking after learning they were pregnant and are motivated to stay abstinent
      postpartum. Participants will be randomized to receive extended-release bupropion (active
      300mg or placebo once daily beginning 4 to 10 days postpartum to 12 weeks
      post-randomization). All participants will complete the same data collection procedures
      (e.g., biological sample collection for hormone and cotinine analysis and completion of
      validated questionnaires) at baseline (gestational week 36), weekly from 4 to 10 days
      postpartum through 12 weeks post-randomization and at weeks 12, 24, 36 and 52
      post-randomization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Point prevalence smoking abstinence</measure>
    <time_frame>24 weeks post randomization</time_frame>
    <description>7-day point prevalence abstinence</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Postpartum Smoking Relapse</condition>
  <arm_group>
    <arm_group_label>Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to extended-release bupropion. Once-daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to placebo. Once-daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion Extended Release Oral Tablet</intervention_name>
    <description>12 weeks postpartum of blinded study medication</description>
    <arm_group_label>Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>12 weeks postpartum of blinded placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide informed consent

          -  Age 18 to 40 years old

          -  Stable health

          -  7-day point prevalence abstinence demonstrated at randomization

          -  Lifetime history of at least 100 cigarettes smoked

          -  Quit smoking during the current pregnancy

          -  Self-report of intention to remain abstinent after delivery ≥ 7 on a 10 point
             Likert-type scale

          -  Uncomplicated delivery

          -  Denies plans to become pregnant again during the trial.

          -  Full-term delivery ≥ 37 weeks gestation

          -  Home within 10 days of delivery

        Exclusion Criteria:

          -  Current use of other forms of tobacco or nicotine (e-cigs, chew, snuff, etc.)

          -  Current use of cessation aids (e.g., varenicline, NRT)

          -  Current use of illicit drugs or alcohol dependence

          -  Current use of antidepressant medication

          -  Bipolar disorder, eating disorder, or psychotic disorder based on the Structured
             Clinical Interview

          -  Medications &amp; conditions that may increase the risk of taking bupropion (e.g., current
             or history of pulmonary embolus, stroke, heart disease, kidney disease, glaucoma,
             diabetes, seizure disorder, traumatic head injury, use of medications metabolized by
             CYP2D6)

          -  Family history of seizures or seizure disorder

          -  Maternal use of medications that lower seizure threshold

          -  Newborn with an elevated risk of seizure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Individuals eligible for this study must be pregnant at the time of enrollment.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Allen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Harrison, MPH</last_name>
    <phone>612-624-5377</phone>
    <email>harr0644@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Allen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Only de-identified data collected in this trial may be available to other researchers. Requests for data will be considered on an individual basis by the study team.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

